Navigation Links
EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
Date:1/3/2008

ROCKVILLE, Md., Jan. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its aurora kinase/angiogenesis inhibitor, ENMD-2076.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

ENMD-2076 is a novel, dual-acting, kinase inhibitor with potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple xenograft models, including tumor regression in breast, colon, and leukemia models. Importantly, ENMD-2076 is an oral agent that has shown an acceptable toxicity profile in preclinical studies without cardiovascular effects.

Carolyn F. Sidor, MD, MBA, EntreMed Vice President and Chief Medical Officer commented on the IND, "Acceptance of the Investigational New Drug application for ENMD-2076 initiates the clinical program for our first compound that targets kinases. This is an exciting class of compounds with several recently approved in oncology indications. ENMD-2076 is unique in class because it not only inhibits Aurora A selectively over Aurora B, it also inhibits a number of other kinases important in the growth of tumors and, in particular, growth factor receptors critical to angiogenesis. ENMD-2076 has potent antitumor activity
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Aug. 26, 2014  NeuroSigma, Inc., a ... develop bioelectronic technologies, today announced that it has filed ... Securities and Exchange Commission relating to a proposed initial ... shares to be offered and the price range for ... Jefferies LLC will act as the book-running manager ...
(Date:8/26/2014)... 2014 An analysis by Replikins, Ltd. of ... Mers CoV virus strains has revealed extensive conservation ... This conservation and sharing of specific Replikin gene structures ... candidate, as it did for the H5N1 influenza vaccine ... have been found to be effective (1,2). ...
(Date:8/26/2014)... A team of engineers from Singapore has successfully ... (WSN) for satellite communications. , With the weight ... design, constructing a lightweight, low power-consuming, wireless communication ... satellite has always been a challenge for system ... Research Centre of Nanyang Technological University in Singapore ...
(Date:8/26/2014)... , August 26, 2014 , ... hospitals with surgery validation using its Stratasys Objet24 and Objet30 ... surgery on 3D printed models prior to operations reduces theatre ... effective aid for both patient and surgeon   ... a global leader of 3D printing and additive manufacturing solutions, ...
Breaking Biology Technology:ZigBee in the Sky 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5
... the Board ... Neill Named President, ISELIN, N.J., Jan. 3 Pharmos Corporation,(Nasdaq: ... effective immediately., Board Changes, Robert F. Johnston has been elected ... and Mony Ben Dor have retired from,the Board., The Pharmos Board ...
... Jan. 3 Cambrex,Corporation (NYSE: CBM ) ... President and Chief Executive Officer, will make a ... on January 8, 2008 at,9:00 a.m. PST at ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), A live ...
... Manufacture; Genzyme will Continue to Market and ... ... CAMBRIDGE, Mass., Jan. 3 ,BioMarin Pharmaceutical Inc. (Nasdaq and SWX: ... restructuring of their joint venture,regarding Aldurazyme(R) (laronidase). Under the revised ...
Cached Biology Technology:Pharmos Corporation Announces Board and Management Changes 2Pharmos Corporation Announces Board and Management Changes 3BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 2BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 3BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 4BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 5
(Date:8/25/2014)... study reveals that the US has experienced widespread ... prostate cancer in recent years. The BJU ... surgeries are more expensive than traditional surgeries, their ... surgeons began using robotic technologies in operations to ... use of such robotic-assisted radical prostatectomy (RARP) procedures ...
(Date:8/25/2014)... of the most widespread causes of reduced crop yield. ... are plagued by boron deficient soil and, often, corn ... with boron; however, little is known about the ways ... researchers at the University of Missouri have found that ... in corn plants. Scientists anticipate that understanding how corn ...
(Date:8/25/2014)... promotes virus entry into cells also has the ability ... University of Missouri researchers have found. , "This is ... understanding of not only HIV infection, but also that ... Ph.D., associate professor in the MU School of Medicine,s ... was recently published in the Proceedings of the ...
Breaking Biology News(10 mins):US has seen widespread adoption of robot-assisted cancer surgery to remove the prostate 2Researchers find boron facilitates stem cell growth and development in corn 2MU researchers discover protein's ability to inhibit HIV release 2MU researchers discover protein's ability to inhibit HIV release 3
... system, every protein made in the cell has a specific ... proteins to their appropriate target. Researchers at Boston University ... images of these channels as they open to allow proteins ... made. These findings are published as a Letter in ...
... apps, cameras, and mobile internet to navigate strange cities in ... in line, and upload their videos directly to social media ... high-tech savvy can save a well-loved device from dying when ... same basic ailment that plagues solar power plants and wind ...
... A drug currently on the market to treat leukemia reversed ... findings by medical researchers with the University of Alberta. ... team,s discovery in the peer-reviewed journal, PLOS ONE . ... can also play an important role in the development of ...
Cached Biology News:Researchers capture images of open channel that moves proteins across cell membranes 2Futuristic copper foam batteries get more bang for the buck 2Futuristic copper foam batteries get more bang for the buck 3UAlberta medical researchers discover potential new treatment for colitis 2UAlberta medical researchers discover potential new treatment for colitis 3
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
GOAT ANTI FRK...
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: